The Power of Precision CD8+ tLNPs
The promise of in vivo cell therapy is immense: rewriting, engineering, or repairing cells directly inside the human body without the complex, costly infrastructure of traditional ex vivo manufacturing. But to transition this promise from theory to clinical reality, the industry must overcome its single greatest bottleneck: delivery.
Historically, standard lipid nanoparticles (LNPs) have been bound by default biological constraints—overwhelmingly trafficking to the liver. Unlocking the true potential of systemic in vivo therapeutics requires an escape from liver tropism. It demands absolute, cell-type-specific selectivity.
At Tiva Biosciences, we designed our targeted lipid nanoparticle (tLNP) technologies to solve this exact problem. Our goal is to make precision extrahepatic delivery accessible, scalable, and translationally robust. Platform maturity is earned through rigorous iteration; to date, we have completed 1,000+ LNP formulation runs, providing our biopharma partners with the predictable hardware they need to hit critical pipeline milestones.
Recently, we put our CD8-targeted LNP platform to the ultimate test. To ensure absolute transparency and accuracy, we partnered with ACROBiosystems for an exhaustive, independent validation study.
The data is in—and the readouts establish a new benchmark for precision in vivo T-cell targeting.
The Data: High Efficiency Meets Flawless Specificity
When delivering complex genetic payloads—whether mRNA, non-integrating DNA, or advanced gene-writing constructs—biotech pipelines usually face a painful trade-off between delivery efficiency and off-target safety. The independent results from ACROBiosystems prove that our tLNP platform delivers both.
High Transfection Efficiency
In resting primary CD8+ T cells across human peripheral blood mononuclear cell (hPBMC) samples, our platform achieved ~88% target gene expression. Delivering genetic material to resting primary immune cells is notoriously difficult, making this high-efficiency threshold a massive victory for scalable in vivo engineering.
Absolute Lineage Specificity
Efficiency means nothing if your therapeutic payload misfires into neighboring cell populations. The validation study confirmed <1% non-specific uptake in CD4+ helper T cells. This level of lineage-specific precision ensures that therapeutic adjustments are isolated entirely to the intended cytotoxic T-cell populations, drastically lowering off-target safety risks.
True Plug-and-Play Modularity
Advanced targeting shouldn't require rebuilding your manufacturing workflow from scratch. The study demonstrated that our Ready-to-Target binder kit successfully converted standard LNPs into highly selective CD8-tLNPs using a simple, straightforward mixing protocol.
Redefining What’s Possible for In Vivo Pipelines
We want to extend a massive thank you to the team at ACROBiosystems for their rigorous evaluation, scientific diligence, and collaborative spirit throughout this validation process.
For biopharma innovators pushing the boundaries of oncology, autoimmunity, and hematology, precision tropism is no longer a luxury—it is the foundational requirement for the next generation of medicine. Whether you are scaling an early-stage discovery program or optimizing a translationally robust candidate for the clinic, your software deserves shipping hardware that hits the mark every single time.
Accelerate Your Target Selectivity
We don't just promise extrahepatic targeting; we back it up with independent, high-fidelity data. Let’s connect to discuss how Tiva Biosciences can engineer custom ligand-functionalized tLNPs to unlock the full potential of your therapeutic pipeline.
👉 [Contact our team today to request a technical consultation or explore our Ready-to-Target Binder Kits.]
